{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:45:10Z","timestamp":1792424710125,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-13284-5","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T10:31:20Z","timestamp":1734517880000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluate the renal system damage caused by zoledronic acid: a comprehensive analysis of adverse events from FAERS"],"prefix":"10.1186","volume":"24","author":[{"given":"Zhaojun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"13284_CR1","unstructured":"FDA. Zoledronic Acid Injection. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/203231s015s016s017lbl.pdf. Accessed Sep 1, 2024."},{"key":"13284_CR2","doi-asserted-by":"publisher","first-page":"961941","DOI":"10.3389\/fphar.2022.961941","volume":"13","author":"B Wang","year":"2022","unstructured":"Wang B, Zhan Y, Yan L, Hao D. How zoledronic acid improves osteoporosis by acting on osteoclasts. Front Pharmacol. 2022;13:961941.","journal-title":"Front Pharmacol"},{"key":"13284_CR3","doi-asserted-by":"publisher","first-page":"6661534","DOI":"10.1155\/2021\/6661534","volume":"2021","author":"L Liu","year":"2021","unstructured":"Liu L, Geng H, Mei C, Chen L. Zoledronic Acid enhanced the Antitumor Effect of Cisplatin on Orthotopic Osteosarcoma by ROS-PI3K\/AKT signaling and attenuated Osteolysis. Oxid Med Cell Longev. 2021;2021:6661534.","journal-title":"Oxid Med Cell Longev"},{"issue":"10","key":"13284_CR4","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/jbmr.2058","volume":"28","author":"PD Miller","year":"2013","unstructured":"Miller PD, Jamal SA, Evenepoel P, et al. Renal safety in patients treated with bisphosphonates for osteoporosis: a review. J Bone Min Res. 2013;28(10):2049\u201359.","journal-title":"J Bone Min Res"},{"key":"13284_CR5","unstructured":"FDA. FDA Drug Safety Communication. New contraindication and updated warning on kidney impairment for Reclast (zoledronic acid). https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-new-contraindication-and-updated-warning-kidney-impairment-reclast. Accessed Sep 1, 2024."},{"issue":"1","key":"13284_CR6","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1038\/s41598-023-50013-7","volume":"14","author":"V Eshwar","year":"2024","unstructured":"Eshwar V, Kamath A. Assessment of safety profile of secukinumab in real-world scenario using United States food and drug administration adverse event reporting system database. Sci Rep. 2024;14(1):1222.","journal-title":"Sci Rep"},{"key":"13284_CR7","doi-asserted-by":"publisher","first-page":"1225919","DOI":"10.3389\/fphar.2023.1225919","volume":"14","author":"S Su","year":"2023","unstructured":"Su S, Wu L, Zhou G, et al. Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS). Front Pharmacol. 2023;14:1225919.","journal-title":"Front Pharmacol"},{"key":"13284_CR8","unstructured":"FDA Questions. and Answers on FDA\u2019s Adverse Event Reporting System (FAERS). https:\/\/www.fda.gov\/drugs\/surveillance\/questions-and-answers-fdas-adverse-event-reporting-system-faers. Accessed Sep 1, 2024."},{"key":"13284_CR9","doi-asserted-by":"publisher","first-page":"764279","DOI":"10.3389\/fphar.2021.764279","volume":"12","author":"R Umetsu","year":"2021","unstructured":"Umetsu R, Tanaka M, Nakayama Y, et al. Neuropsychiatric adverse events of Montelukast: an analysis of real-world datasets and drug-gene Interaction Network. Front Pharmacol. 2021;12:764279.","journal-title":"Front Pharmacol"},{"issue":"3","key":"13284_CR10","first-page":"422","volume":"48","author":"X Wu","year":"2023","unstructured":"Wu X, Zhang L, Huang H, et al. Signal mining and analysis for central nervous system adverse events due to taking oxycodone based on FAERS database. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023;48(3):422\u201334. English, Chinese.","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"issue":"1","key":"13284_CR11","doi-asserted-by":"publisher","first-page":"25712","DOI":"10.1038\/s41598-024-77889-3","volume":"14","author":"S Wu","year":"2024","unstructured":"Wu S, Hu W, Chen M, Xiao X, Liu R. A real-world pharmacovigilance study of FDA adverse event reporting system events for Lutetium-177-PSMA-617. Sci Rep. 2024;14(1):25712.","journal-title":"Sci Rep"},{"issue":"1","key":"13284_CR12","doi-asserted-by":"publisher","first-page":"20601","DOI":"10.1038\/s41598-022-23726-4","volume":"12","author":"M Guo","year":"2022","unstructured":"Guo M, Shu Y, Chen G, et al. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib. Sci Rep. 2022;12(1):20601.","journal-title":"Sci Rep"},{"issue":"1","key":"13284_CR13","doi-asserted-by":"publisher","first-page":"19587","DOI":"10.1038\/s41598-024-69614-x","volume":"14","author":"HJ Kim","year":"2024","unstructured":"Kim HJ, Yoon JH, Park YH. Long-term hepatobiliary disorder associated with trastuzumab emtansine pharmacovigilance study using the FDA adverse event reporting System database. Sci Rep. 2024;14(1):19587.","journal-title":"Sci Rep"},{"issue":"17","key":"13284_CR14","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s40265-016-0662-4","volume":"76","author":"S Dhillon","year":"2016","unstructured":"Dhillon S. Zoledronic acid (Reclast\u00ae, Aclasta\u00ae): a review in osteoporosis. Drugs. 2016;76(17):1683\u201397.","journal-title":"Drugs"},{"issue":"11","key":"13284_CR15","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1038\/ki.2008.356","volume":"74","author":"MA Perazella","year":"2008","unstructured":"Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int. 2008;74(11):1385\u201393.","journal-title":"Kidney Int"},{"key":"13284_CR16","doi-asserted-by":"crossref","unstructured":"Yachoui R. Early onset acute tubular necrosis following single infusion of zoledronate. Clin Cases Min Bone Metab 2016 May-Aug;13(2):154\u20136.","DOI":"10.11138\/ccmbm\/2016.13.2.154"},{"issue":"9","key":"13284_CR17","first-page":"582","volume":"10","author":"A Mahindra","year":"2012","unstructured":"Mahindra A, Pozzi S, Raje N. Clinical trials of bisphosphonates in multiple myeloma. Clin Adv Hematol Oncol. 2012;10(9):582\u20137.","journal-title":"Clin Adv Hematol Oncol"},{"key":"13284_CR18","doi-asserted-by":"publisher","first-page":"115390","DOI":"10.1016\/j.bone.2020.115390","volume":"137","author":"IR Reid","year":"2020","unstructured":"Reid IR, Green JR, Lyles KW, Reid DM, Trechsel U, Hosking DJ, Black DM, Cummings SR, Russell RGG, Eriksen EF. Zoledronate Bone. 2020;137:115390.","journal-title":"Zoledronate Bone"},{"issue":"1","key":"13284_CR19","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00204-017-2048-0","volume":"92","author":"L Cheng","year":"2018","unstructured":"Cheng L, Ge M, Lan Z, et al. Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity. Arch Toxicol. 2018;92(1):469\u201385.","journal-title":"Arch Toxicol"},{"issue":"1","key":"13284_CR20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1159\/000527931","volume":"48","author":"Y Wu","year":"2023","unstructured":"Wu Y, Ma T, Yu X, Su T. Severe hypophosphatemia as the initial presentation of Renal Fanconi\u2019s syndrome and distal renal tubular acidosis related to Zoledronic Acid: a Case Report and Literature Review. Kidney Blood Press Res. 2023;48(1):18\u201327.","journal-title":"Kidney Blood Press Res"},{"issue":"1","key":"13284_CR21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00204-014-1237-3","volume":"89","author":"P Jennings","year":"2015","unstructured":"Jennings P, Crean D, Aschauer L, et al. Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015;89(1):101\u20136.","journal-title":"Arch Toxicol"},{"issue":"2","key":"13284_CR22","first-page":"555757","volume":"9","author":"S Bouomrani","year":"2018","unstructured":"Bouomrani S, Rega\u00efeg N, Nefoussi M, Trabelsi S. Zoledronic Acid-Induced Acute Renal failure in multiple myeloma. JOJ Case Stud. 2018;9(2):555757.","journal-title":"JOJ Case Stud"},{"issue":"3","key":"13284_CR23","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.kint.2020.11.010","volume":"99","author":"F Bridoux","year":"2021","unstructured":"Bridoux F, Leung N, Belmouaz M, Royal V, Ronco P, Nasr SH, Fermand JP, International Kidney and Monoclonal Gammopathy Research Group. Management of acute kidney injury in symptomatic multiple myeloma. Kidney Int. 2021;99(3):570\u201380.","journal-title":"Kidney Int"},{"key":"13284_CR24","doi-asserted-by":"publisher","first-page":"1369118","DOI":"10.3389\/fimmu.2024.1369118","volume":"15","author":"Q Li","year":"2024","unstructured":"Li Q, Lin J, Hao G, Xie A, Liu S, Tang B. Nephrotoxicity of targeted therapy used to treat lung cancer. Front Immunol. 2024;15:1369118.","journal-title":"Front Immunol"},{"key":"13284_CR25","volume-title":"Pediatric Nephrology","author":"T Igarashi","year":"2021","unstructured":"Igarashi T, Emma F, Hayes W. Pediatric Fanconi Syndrome. In: Emma F, Goldstein S, Bagga A, Bates CM, Shroff R, editors. Pediatric Nephrology. Berlin, Heidelberg: Springer; 2021."},{"issue":"23","key":"13284_CR26","first-page":"232","volume":"23","author":"T Gnanadeepan","year":"2020","unstructured":"Gnanadeepan T, Mayilananthi K, Gaurav N, Durga K. Transient renal tubular dysfunction following Zoledronic acid treatment. Annals Trop Med Public Health. 2020;23(23):232\u2013355.","journal-title":"Annals Trop Med Public Health"},{"issue":"3","key":"13284_CR27","doi-asserted-by":"publisher","first-page":"184","DOI":"10.32932\/pjnh.2019.10.038","volume":"33","author":"M Oliveira","year":"2019","unstructured":"Oliveira M, Santos MT, Costa A. Fanconi syndrome related to zoledronic acid. Portuguese J Nephrol Hypertens. 2019;33(3):184\u20137.","journal-title":"Portuguese J Nephrol Hypertens"},{"issue":"4","key":"13284_CR28","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1053\/j.ajkd.2021.12.015","volume":"80","author":"I Portales-Castillo","year":"2022","unstructured":"Portales-Castillo I, Mount DB, Nigwekar SU, Yu EW, Rennke HG, Gupta S. Zoledronic Acid-Associated Fanconi Syndrome in patients with Cancer. Am J Kidney Dis. 2022;80(4):555\u20139. https:\/\/doi.org\/10.1053\/j.ajkd.2021.12.015. Epub 2022 Feb 24.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"13284_CR29","doi-asserted-by":"publisher","first-page":"e0121861","DOI":"10.1371\/journal.pone.0121861","volume":"10","author":"A Verhulst","year":"2015","unstructured":"Verhulst A, Sun S, McKenna CE, D\u2019Haese PC. Endocytotic uptake of zoledronic acid by tubular cells may explain its renal effects in cancer patients receiving high doses of the compound. PLoS ONE. 2015;10(3):e0121861.","journal-title":"PLoS ONE"},{"key":"13284_CR30","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"F Saad","year":"2002","unstructured":"Saad F, Gleason DM, Murray R, et al. Zoledronic acid prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458\u201368.","journal-title":"J Natl Cancer Inst"},{"key":"13284_CR31","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/ki.2008.193","volume":"74","author":"S Boonen","year":"2008","unstructured":"Boonen S, Sellmeyer DE, Lippuner K, et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int. 2008;74:641\u20138.","journal-title":"Kidney Int"},{"issue":"11","key":"13284_CR32","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1007\/s00198-022-06499-4","volume":"33","author":"CW Fixen","year":"2022","unstructured":"Fixen CW, Fixen DR. Renal safety of zoledronic acid for osteoporosis in adults 75 years and older. Osteoporos Int. 2022;33(11):2417\u201322.","journal-title":"Osteoporos Int"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13284-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-13284-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13284-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T11:06:46Z","timestamp":1734520006000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-13284-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["13284"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-13284-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5106994\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"18 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. Ethical approval was not required for this study because we used the FAERS database, which is a free open-access database.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1520"}}